Australia Diabetes Market Forecast Report by Type, End User, States and Company Analysis 2026-2034

Australia Diabetes Market was US$ 3.94 Billion in 2022

The Australia Diabetes Device Market is forecasted to grow from US$ 662.81 Million in 2025 to US$ 1.24 billion in 2034, registering a CAGR of 7.28% between 2026 and 2034. The factors that fuel the growth of the Australia Diabetes Device Market are the growing incidence rates of diabetes, robust government support for healthcare systems, and the surging interest in utilizing latest technological innovations in diabetes management, including Continuous Glucose Monitors and insulin pumps.

Australia Diabetes Device Market Outlook

A diabetes device refers to a medical device intended to assist individuals in the monitoring of their blood glucose and insulin administration, and it significantly plays an important role in managing people with diabetes and making sure that related complications are averted. The types of devices for people who are diabetic include SMBG meters, insulin pens, insulin pumps, and CGM devices. Digital health innovations have significantly improved the management of diabetes through devices, as these devices are connected to smartphones and are able to analyze data.

In Australia, the usage of diabetes care devices remains popular because of the high prevalence rate and the availability of an excellent public health care system in the country. Reimbursement schemes and health insurance plans provided by the government and other companies in the country make it easier for patients to access glucose and insulin delivery devices and systems. Doctors also recommend the usage of devices as an effective way to prevent frequent admissions to health care centers and associated complications arising out of the disease. Further, the scattered population in Australia leads to an increase in the need for home and self-care services.

Drivers of the Australian Diabetes Devices Market

Increasing Diabetes Rates & Aging Population

Over 16% of the population of Australia is already over 65. This is likely to rise to nearly 1 in 4, or 4.5 million, by 2066. Diabetes is continuing to rise steadily in the Australian population due to lifestyle issues such as physical inactivity, obesity, and changes to diet. Type 2 diabetes is especially prevalent among the older patients. Hence, the growth due to aging is especially significant for the market of diabetes devices. Also, since patients are expected to live longer with the condition, there is likely to be an increasing requirement for long-term management of the disease, including increasing usage of SMBG devices, CGM systems, insulin pens, and insulin pumps. Older patients are exposed to serious complications. Hence, healthcare professionals are increasing the demand for constant monitoring to ensure good control of the condition. Devices which can help patients to monitor and manage the condition from the comfort of their homes and decrease the demand to visit healthcare settings are especially sought after. Thus, the patient base is expected to be highly supportive of the growth of the diabetes market. Today, there are about 1.9 million diabetic patients in Australia. This includes about 1.5 million people who are already known and registered as patients with all forms of diabetes. A further 500,000 patients already have yet-to-be-diagnosed Type 2 diabetes.

Strong Government Support System & Reimbursement Mechanism

The healthcare provision in Australia giving comprehensive support for diabetes care through funding mechanisms. The funding of glucose meters, insulin delivery pens, and consumables by healthcare programs lessens any associated costs for men and women in the country. Government-supported programs for diabetes prevention and control stimulate men and women to seek early diagnosis and frequent glucose monitoring. Docile doctors can now prescribe innovative devices due to supported affording mechanisms, pushing forward the adoption of CGM and Insulin delivery pens swiftly. The stable environment provided by funding certainty in turn fosters favorable market conditions for glucose meter/consumable manufacturers and distributors of insulin delivery pens too. Supportive policies relate well to overall national agendas concerning favourable future healthcare expenditure due to avoided complications of diabetes, thereby making healthcare fund support and government encouragement an important stimulator of growth of diabetes care markets. Health promotion and health protection and disease prevention programs that aim at achieving an improvement in health and working on factors causing ill-health.

Difficulties in the Australia Diabetes Devices Market

High Device and Material Expenditures

Despite the support for reimbursement, the price of diabetes technology, especially innovative technologies like continuous glucose monitoring systems and insulin pumps, still presents a challenge in Australia. This can be a concern for patients who have to pay for sensors, consumables, or upgrades for devices, thereby hindering long-term compliance. This pricing sensitivity can be pronounced for low-socioeconomic groups or those on continuous therapy. The pricing constraint for manufacturers, on the other hand, could come from insurance companies or the government, thereby potentially limiting profit, especially for innovative technologies.

Access Barriers in Rural and Remote Areas

Australia’s large geography results in inconsistencies in the accessibility of diabetes technology and specialist services, especially for rural and remote populations. Inadequate presence of qualified healthcare personnel may hinder the diagnosis, introduction, and education of patients on the technology. The latest technology, like insulin pumps and CGM, might need specialist support, which may not be readily available, especially in the rural areas. Telehealth has been useful in overcoming the challenges, but the accessibility of diabetes technology products remains an important issue for the healthcare system in Australia.

Australia SMBG Device Market

The SMBG market in Australia remains an important part of diabetes care, especially in type 2 diabetic patients, early diagnosis, and in those not on continuous glucose monitoring systems yet. SMBG glucose meters and test strips are common tools in clinical practice to enable glucose monitoring on a day-to-day basis, especially during drug therapy adjustments and lifestyle modifications. Government subsidy schemes and insurance coverage ensure greater accessibility, especially in the geriatric population and in rural areas of Australia. Although CGM usage is on an uptrend, SMBG remains an important adjunct tool in confirmation and short-term monitoring. Currently, competition in the SMBG market in Australia is based on precision, simplicity, lower blood requirements, and connectivity with mobile tools that record glucose reading patterns. The SMBG market in Australia is established and quite stable due to widespread patient acceptance, ease of accessibility, and relevance in traditional diabetes care practices.

Australia CGM Device Market

The market for CGM technology in Australia is among the most rapidly growing in the diabetes technology industry, driven by the growing awareness of the benefits of real-time glucose tracking. The use of CGM technology is becoming widespread in the prescribed treatment of type 1 diabetic patients, as well as type 2 diabetic patients who rely on insulin. This technology has greatly gained popularity in Australia, especially with the development of the telehealth system that enables the transfer of CGM data from the patients to the doctors for observation and analysis. This has greatly pleased the clients, especially in relation to the elimination of the pain associated with the traditional measuring process, in addition to the improvement in the standard of living. Additionally, the support by the Australian government in the reimbursement process has greatly enhanced the use of the technology.

Australia Insulin Pump Device Market

The insulin pump industry in Australia remains fairly specialized, with its primary target base comprising patients with type 1 diabetes and carefully selected patients with type 2 diabetes who require intense insulin management. Insulin pumps are primarily prescribed by specialized diabetic treatment centers and hospital authorities, where formal education support facilities are offered. The demand for flexible insulin management, precision dosing, and improved glycemic control fuels the expansion of the insulin pump industry in Australia. The addition of CGI technologies to insulin pumps provides added advantages by facilitating semi-autonomous insulin administration and insulin management based on analytical insights. High purchase costs, along with the requirement of special patient training, are some factors that impede the widespread adoption of insulin pumps in Australia.

Australia Insulin Pen Device Market

The insulin pen has been recognized as the most common type of insulin delivery systems being widely utilized in Australia owing to their convenience, precision, and handling ease. These systems have been found highly useful and preferred by type 2 diabetic patients as well as geriatric patients who show strong favor towards simple and reliable systems easily available at home. Prefilled pen systems as well as reusable pen systems have been found to save preparation time, show less likelihood of dosing error, and show strong adherence as compared to vial and syringe systems. Market dynamics focus on the design, precision, safety, and utility with respect to different types of insulins being developed every day. "Connected" insulin pens with the ability to record and link dosing data have also slowly begun attracting notice."

Australian Diabetes Devices Hospital Market

The role of hospitals is quite important in the Australian diabetes device market, especially when it comes to the diagnosis of diabetes and the initiation of therapy. First uses of SMBG systems, CGM systems, and insulin pumps occur quite often during a patient’s stay in a hospital. Hospitals help patients through education and training provided by the diabetes team. This is quite important when we consider the need for training of patients when they use advanced technologies. Hospitals play a significant role in deciding the procurement of the device depending upon guidelines and reimbursements. This ensures a steady stream of demand for diabetes devices within the hospitals segment.

Australia Diabetes Device Homecare Market

The homecare market for people with diabetes in Australia has been rapidly expanding with the rise in the number of people managing their condition outside the healthcare setting. Regional dissemination and satisfactory connectivity facilitate home-based management systems such as SMBG monitors, CGM, insulin pens, and connected devices. The need for convenience, autonomy, and avoiding travel for regular healthcare continues to appreciate the home-based approach for those with diabetes, especially living in rural and remote areas of the country. Telehealth services enable healthcare professionals to view the outputs of homecare devices, catering to personalized chronic treatment and prevention strategies. In support of home-based healthcare, the government continues to encourage the management of chronic conditions such as diabetes. The homecare market continues to be a driving force in the management of people with diabetes, especially with the shift to people-centered healthcare approaches.

Victoria Diabetes Device Market

One of the most advanced diabetic care markets in the Australian setting is the Victoria diabetic care market, with a comprehensive public healthcare system and minimal diabetic care technology gaps compared to other regions and countries. Melbourne and other urban areas create demand for the more advanced diabetic care solutions like CGM, insulin pumps, and smart insulin pens, while the public has high health literacy and is more willing to embrace digital health solutions that integrate data sharing and online monitoring. Public hospitals and specialist care facilities also create the primary demand for the more advanced solutions, while public pharmacies and online services drive the SMBG and insulin pens’ availability and sales. The growing population of seniors and rising prevalence of type 2 diabetics also create demand for SMBG and insulin pens.

Queensland Diabetes Device Market

The diabetes devices market in Queensland is influenced by its geographical spread and the amalgamation of an urban and regional population with an increasing prevalence of diabetes. There is a high demand for SMBG systems and insulin pens in the region, which are beneficial for self-management in regional and rural areas, with restricted access to specialist care. CGM systems are also gaining acceptance in the region with the availability of telehealth services, through which the treating physician can monitor and manage the patient’s condition with less need to visit the patient in person. In the major cities, including Brisbane, the hospitals function as initiating sites in the usage of advanced systems, and home care dominates the management aspect in the long run. Lifestyle and aging are other causes of an increasing prevalence of diabetes in the region.

The South Australian Diabetes Devices Market

The South Australian diabetes market is driven by an ageing population that requires chronic disease management. The use of SMBG, insulin pens; and to some extent, CGM, insulin pumps, is common, but it is being adopted in an controlled fashion through specialist clinics and hospitals in the main cities like Adelaide. The high cost sensitivity in this market affects new technology adoption in favor of mature technologies that are known to be mature and reliable. The South Australian market is characterized by hospitals and community pharmacies, but with an increasing contribution from the homecare market. The South Australian market is generally stable and driven by volumes.

Tasmania Diabetes Devices Market

The diabetes market in Tasmania is of smaller proportions and is very significant from the standpoint of chronic diseases. Tasmania has the second-highest incidence of diabetes in Australia. This can be attributed to relevant demographic issues, lifestyle risks, and the older population. The demand is likely to be focused on SMBG systems and insulin pens, which will help the patient monitor and manage the condition. While access to advanced technology such as CGM and insulin pumps is restricted and usually organized from the larger hospitals, the distribution constraints and healthcare environments are creating a need to manage this condition from the remotest possible geographies. Telemedicine and home-delivery models are assuming significance. The Tasmania market is primed to be very focused on the notion of access and affordability and enabling the patient to manage his/her condition from the remotest corner of the healthcare-environment.

Market Segmentation

Type

• Self-Monitoring Devices
• Continuous Glucose-Monitoring Devices
• Insulin Pumps
• Insulin Pens

End User

• Hospitals
• Diagnostics Centers
• Homecare

States

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Australian Capital Territory
• Tasmania
• Northern Territory

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue

Company Analysis

• Novo Nordisk A/S
• Eli Lilly
• Roche
• Abbott Laboratories
• Insulet Corporation
• Dexcom Inc
• Medtronic
• Ypsomed AG